PreveCeutical Medical Inc.
PRVCF
$0.02
$0.002.37%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -43.16% | 82.13% | |||
| Depreciation & Amortization | -10.34% | 31.82% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -39.84% | 84.16% | |||
| Operating Income | 39.84% | -84.16% | |||
| Income Before Tax | 31.31% | -70.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 31.31% | -70.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 31.31% | -70.46% | |||
| EBIT | 39.84% | -84.16% | |||
| EBITDA | 39.94% | -84.41% | |||
| EPS Basic | 31.25% | -60.00% | |||
| Normalized Basic EPS | 30.00% | -66.67% | |||
| EPS Diluted | 31.25% | -60.00% | |||
| Normalized Diluted EPS | 30.00% | -66.67% | |||
| Average Basic Shares Outstanding | 1.84% | 4.79% | |||
| Average Diluted Shares Outstanding | 1.84% | 4.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||